Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
NCC Doctor Hails MHLW’s Policy on Use of Clinical Research Data in Regulatory Filing
A doctor of the National Cancer Center Hospital well-versed in operating clinical research has welcomed a recent move by the Japanese health ministry to provide its basic policy for the use of data from so-called “specified clinical research” in regulatory…
To read the full story
Related Article
- MHLW to Make Case-by-Case Decisions on Use of “Specified Clinical Research” Data in Regulatory Filings
April 6, 2023
- Label Expansion for TS-1, Enhertu and More in Line for November Approval
November 1, 2022
- MHLW Presents Policy for Use of “Specified Clinical Research” Data in Regulatory Submissions
April 4, 2022
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…